Literature DB >> 12223302

Further modification of the Hodge test to screen AmpC beta-lactamase (CMY-1)-producing strains of Escherichia coli and Klebsiella pneumoniae.

Dongeun Yong1, Rojin Park, Jong Hwa Yum, Kyungwon Lee, Eung Chil Choi, Yunsop Chong.   

Abstract

Cefoxitin-resistant Escherichia coli and Klebsiella pneumoniae are widespread in Korea. Significant proportions of them are considered to be CMY-1 producers. For effective screening of CMY-1 producers, the Hodge test was modified by using a cefoxitin disk and the performance was evaluated. The sensitivity and specifity of the test were 100% and 94.9%, respectively. The test was easier to perform than the three-dimensional extract test. This modified test should be suitable for screening CMY-1-producing strains of E. coli and K. pneumoniae. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12223302     DOI: 10.1016/s0167-7012(02)00053-2

Source DB:  PubMed          Journal:  J Microbiol Methods        ISSN: 0167-7012            Impact factor:   2.363


  12 in total

1.  Use of beta-lactamase inhibitors in disk tests to detect plasmid-mediated AmpC beta-lactamases.

Authors:  Jennifer A Black; Kenneth S Thomson; Johann D D Pitout
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

2.  Plasmid-mediated quinolone resistance in extended-spectrum-β-lactamase- and AmpC β-lactamase-producing Serratia marcescens in China.

Authors:  Hai-Fei Yang; Jun Cheng; Li-Fen Hu; Ying Ye; Jia-Bin Li
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

3.  AmpC disk test for detection of plasmid-mediated AmpC beta-lactamases in Enterobacteriaceae lacking chromosomal AmpC beta-lactamases.

Authors:  Jennifer A Black; Ellen Smith Moland; Kenneth S Thomson
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

Review 4.  Extended-spectrum-beta-lactamase, AmpC, and Carbapenemase issues.

Authors:  Kenneth S Thomson
Journal:  J Clin Microbiol       Date:  2010-02-24       Impact factor: 5.948

5.  Evaluation of beta-lactamase inhibitors in disk tests for detection of plasmid-mediated AmpC beta-lactamases in well-characterized clinical strains of Klebsiella spp.

Authors:  Jennifer A Black; Kenneth S Thomson; John D Buynak; Johann D D Pitout
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

6.  Practical methods using boronic acid compounds for identification of class C beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.

Authors:  Tetsuya Yagi; Jun-ichi Wachino; Hiroshi Kurokawa; Satowa Suzuki; Kunikazu Yamane; Yohei Doi; Naohiro Shibata; Haru Kato; Keigo Shibayama; Yoshichika Arakawa
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

7.  Multiplex PCR to detect pAmpC β-lactamases among enterobacteriaceae at a tertiary care laboratory in Mumbai, India.

Authors:  Mubin Kazi; Kanchan Ajbani; Jeffrey A Tornheim; Anjali Shetty; Camilla Rodrigues
Journal:  Microbiology (Reading)       Date:  2018-12-13       Impact factor: 2.777

8.  Factors associated with antimicrobial resistance among clinical isolates of Klebsiella pneumoniae: 1-year survey in a French university hospital.

Authors:  C De Champs; C Rich; P Chandezon; C Chanal; D Sirot; C Forestier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-05-18       Impact factor: 3.267

9.  Prevalence of AmpC and other beta-lactamases in enterobacteria at a large urban university hospital in Brazil.

Authors:  Rubens Clayton da Silva Dias; Armando Alves Borges-Neto; Giovanna Ianini D'Almeida Ferraiuoli; Márcia P de-Oliveira; Lee W Riley; Beatriz Meurer Moreira
Journal:  Diagn Microbiol Infect Dis       Date:  2007-09-27       Impact factor: 2.803

10.  High occurrence of blaCMY-1 AmpC lactamase producing Escherichia coli in cases of complicated urinary tract infection (UTI) from a tertiary health care centre in north India.

Authors:  Neelam Taneja; Gagandeep Singh; Meenakshi Singh; Surendra Madhup; Sapna Pahil; Meera Sharma
Journal:  Indian J Med Res       Date:  2012-08       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.